Duloxetine
Product Images NDC 50090-2585

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-2585). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)

A line graph comparing the proportion of patients with relapse over time between two treatment groups: Placebo and Duloxetine. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients experiencing relapse, illustrating that the Duloxetine group has a lower relapse proportion over time than the Placebo group.*

FDA Label Image

Fig2 (Duloxetine Fig2)

A line graph showing the proportion of patients with relapse over time in days from randomization for two treatment groups: placebo (dashed line) and Duloxetine (solid line). The graph compares relapse rates up to approximately 275 days.*

FDA Label Image

Figure 3: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-1)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, illustrating trends in pain improvement among these groups over a range of improvement percentages.*

FDA Label Image

Figure 4: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-2)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo, each represented with distinct markers. The data illustrates trends of improvement in pain across these treatments.*

FDA Label Image

Figure 7: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-1 (Duloxetine Fig5)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups. Both Duloxetine treatments show higher patient improvement percentages than placebo across increasing pain improvement levels.*

FDA Label Image

Figure 8: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-3 (Duloxetine Fig6)

This line graph depicts the percentage of patients reporting improvement versus percent improvement in pain from baseline for Duloxetine at doses of 20 mg, 60 mg, and 120 mg once daily, compared to placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percent of patients improved, with Duloxetine doses consistently showing higher improvement rates than placebo.*

FDA Label Image

Figure 9: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Oa-1 (Duloxetine Fig7)

A line graph comparing percentage improvement in pain from baseline (BOCF) versus percentage of patients improved for Duloxetine 60/120 mg once daily and placebo. The graph shows two curves, one for placebo and one for Duloxetine, with axes labeled as Percent Improvement in Pain from Baseline (horizontal) and Percentage of Patients Improved (vertical).*

FDA Label Image

Duloxetine Fig8

A line graph comparing percentage of patients improved over increasing percent improvement in pain from baseline (BOCF) between Duloxetine 60 mg once daily and placebo. The graph shows two curves, with Duloxetine generally having higher patient improvement percentages across the pain improvement range compared to placebo.*

FDA Label Image

Duloxetine Fig9

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) between Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain, and the y-axis shows percentage of patients improved, with Duloxetine generally showing higher improvement.*

FDA Label Image

Structure (Duloxetine Str)

Chemical structure of Duloxetine hydrochloride, showing its molecular framework including a naphthyl group, a thiophene ring, and an amine with a hydrochloride substituent.*

FDA Label Image

Label Image (Lbl500902585)

Label for Duloxetine 60 mg delayed-release capsules, manufactured by A-S Medication Solutions. The label includes the product NDC 50090-2585-0 and instructs to store the capsules at 60 to 70 degrees Fahrenheit. The package contains 30 delayed-release capsules. Dosage information references a package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.